Karex Berhad, an investment holding company, (5247) Fair Value & Analysis
Consumer Defensive · MY · Market cap 500M MYR
Fair value as of: Jul 19, 2026
From 11 valuation models · updated 22 days ago
Share price +14.0% over the past month.
Below-average quality, and screening another 47% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.2600 MYR). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range 0.3196 MYR – 1.05 MYR · fair‑value band 0.1600 MYR – 0.2600 MYR · the 0.4900 MYR price screens above the 0.2600 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Karex Berhad, an investment holding company, (5247) currently trades at 0.4900 MYR, while our model-based Fair Value estimate is 0.2600 MYR, implying the stock looks roughly 46.9% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Karex Berhad, an investment holding company, generated revenue of 482M MYR at a net margin of -2.7%. Revenue declined 22.2% year over year. It earns a return on equity of -2.8%. Net debt stands at 178M MYR. Fundamentals as of Jul 19, 2026
Our scenario range runs from 0.1600 MYR (bear case) to 0.2600 MYR (bull case); at 0.4900 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 53% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -47%, 5247 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: Asset-Based (0.3000 MYR) versus Earnings-Based (0.0600 MYR). Highest evidence: Residual Income (76).
Notify me when 5247 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Karex Berhad, an investment holding company, manufactures and sells condoms in Malaysia. The company provides personal lubricants; probe covers; and catheters for transurethral drainage of the urinary bladder, as well as gloves. It also offers hand sanitizer and pre-vulcanised latex products.
Full company description
Karex Berhad, an investment holding company, manufactures and sells condoms in Malaysia. The company provides personal lubricants; probe covers; and catheters for transurethral drainage of the urinary bladder, as well as gloves. It also offers hand sanitizer and pre-vulcanised latex products. In addition, the company engages in wholesale healthcare product related business. Karex Berhad operates in the Americas, Asia, Europe, and Africa. Karex Berhad serves brand owners, governments, non-governmental organizations, and retail purchasers. The company was founded in 1988 and is based in Port Klang, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Karex Berhad, an investment holding company, reported revenue of 498M MYR in FY2025 versus 420M MYR in FY2021, a compound +4.4%/yr. Reported net income was 208K MYR in FY2025.
of which total revenue +6.7 pp · buybacks/dilution −2.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
5247 screens 47% overvalued. Compare with The Procter & Gamble Company →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Karex Berhad, an investment holding company, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Karex Berhad, an investment holding company, (5247) overvalued or undervalued?
What is the fair value of 5247?
What is the quality score of 5247?
What is the revenue of Karex Berhad, an investment holding company, (5247)?
What is the net profit margin of 5247?
Does Karex Berhad, an investment holding company, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Karex Berhad, an investment holding company, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.